Recent studies showed that comorbidities such as diabetes, hypertension and obesity
contribute to severe and worse outcomes of coronavirus disease 2019 (COVID-19) …

There is an emergency need for early ambulatory treatment of Coronavirus Disease 2019
(COVID-19) in acutely ill patients in an attempt to reduce disease progression and the risks …

The tropism of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), a virus
responsible for the ongoing coronavirus disease 2019 (COVID-19) pandemic, toward the …

Background Renin‐angiotensin aldosterone system (RAAS) inhibitor—COVID‐19 studies,
observational in design, appear to use biased methods that can distort the interaction …

Background: Hypertension, diabetes, and obesity are common comorbidities that portend
worse outcomes due to coronavirus disease 2019 (COVID-19). Metabolic syndrome is the …

BACKGROUND There is controversy over the effects of angiotensin-converting enzyme
inhibitors (ACEIs) and angiotensin II receptor blockers (ARBs) on the prognosis in patients …

The emergence and global spread of the severe acute respiratory syndrome coronavirus 2
(SARS‐CoV‐2) has resulted in an urgent need for evidence on medical interventions and …

Background Experiences from the first wave of the 2019 coronavirus disease (COVID-19)
pandemic can aid in the development of future preventive strategies. To date, risk prediction …

Background Despite the availability of extensive literature on the effect of angiotensin‐
converting enzyme inhibitors (ACEIs)/angiotensin‐receptor blockers (ARBs) on COVID‐19 …

SARS-CoV-2 infection and its clinical manifestations (COVID-19) quickly evolved to a
pandemic and a global public health emergency. The limited effectivity of available …